CytoDyn (CYDY)

Cash burn rate (est.)	Burn method: Change in cash		Burn method: Operating income		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	21.34 mm	21.34 mm	21.34 mm	21.34 mm	21.34 mm	21.34 mm
Cash burn (monthly)	1.20 mm	(no burn)	1.59 mm	919.83 k	1.20 mm	177.58 k
Cash used (since last report)	2.44 mm	n/a	3.24 mm	1.87 mm	2.44 mm	361.95 k
Cash remaining	18.90 mm	n/a	18.10 mm	19.46 mm	18.90 mm	20.97 mm
Runway (months of cash)	15.8	n/a	11.4	21.2	15.8	118.1

Beta Read what these cash burn values mean

Financial data from CytoDyn earnings reports.

Institutional ownership, Q3 2024

CYDY institutional ownership history Ownership history

0.1% owned by funds/institutions

13F holders	Current	Prev Q	Change
Total holders	7	10	-30.0%
Opened positions	3	4	-25.0%
Closed positions	6	0	NEW
Increased positions	0	1	EXIT
Reduced positions	0	0

13F shares	Current	Prev Q	Change
Total value	48.82 mm	27.91 mm	+74.9%
Total shares	939.15 k	829.62 k	+13.2%
Total puts	0.00	0.00
Total calls	0.00	0.00
Total put/call ratio	–	–	–

Largest owners	Shares	Value	Change
Rosenbaum Paul	635.10 k	$1.33 mm	0.0%
Eagle Bay Advisors	162.11 k	$25.65 mm	NEW
Diversified Trust	45.79 k	$7.25 mm	0.0%
RFP Financial	41.45 k	$6.56 mm	NEW
Next Capital Management	32.50 k	$5.14 mm	NEW
Horizon Financial Services	18.20 k	$2.88 mm	0.0%
Caz Investments	4.00 k	$1.00 k	0.0%

Largest transactions	Shares	Bought/sold	Change
Eagle Bay Advisors	162.11 k	+162.11 k	NEW
Virtue Capital Management	0.00	-45.00 k	EXIT
RFP Financial	41.45 k	+41.45 k	NEW
Next Capital Management	32.50 k	+32.50 k	NEW
Williams Jones Wealth Management	0.00	-25.00 k	EXIT
S.A. Mason	0.00	-19.00 k	EXIT
FineMark National Bank & Trust	0.00	-15.00 k	EXIT
Willis Investment Counsel	0.00	-13.04 k	EXIT
Ancora Advisors	0.00	-9.49 k	EXIT
Caz Investments	4.00 k	0.00	0.0%

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Recent insider trades

CYDY insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
28 Oct 24	Tanya Durkee Urbach	NQSO Common Stock	Grant	Acquire A	No	No	0.13	800,000	104.00 k	800,000
28 Oct 24	Stephen M Simes	NQSO Common Stock	Grant	Acquire A	No	No	0.13	800,000	104.00 k	800,000
28 Oct 24	Lishomwa C Ndhlovu	NQSO Common Stock	Grant	Acquire A	No	No	0.13	800,000	104.00 k	800,000
28 Oct 24	Jacob P Lalezari	NQSO Common Stock	Grant	Acquire A	No	No	0.13	3,000,000	390.00 k	3,000,000
28 Oct 24	Ryan Dunlap	NQSO Common Stock	Grant	Acquire A	No	No	0.13	800,000	104.00 k	800,000

Data from 3, 4 and 5 filings. Values as filed, not updated for current price.

Press releases

From Benzinga Pro

CytoDyn Appoints Richard Pestell, M.D., Ph.D. as Lead Consultant in Oncology

25 Nov 24

VANCOUVER, Washington, Nov. 25, 2024 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB:CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential for

CytoDyn Announces FDA Clearance of Its Phase II Oncology Trial

4 Nov 24

VANCOUVER, Washington, Nov. 04, 2024 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB:CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential for